Press release BoxID: 108118 (Hummingbird Diagnostics GmbH)
  • Hummingbird Diagnostics GmbH
  • Im Neuenheimer Feld 519
  • 69120 Heidelberg
  • Contact person
  • Julia Schliwka
  • +49 (6221) 65176-00

Anthony Caruso Joins febit Team

Former President of Lion Bioscience Research, Inc., Anthony Caruso, brings febit to a new level in Informatics

(PresseBox) (Heidelberg, ) febit inc. announced today the successful completion of negotiations with Anthony Caruso, former President of Lion Bioscience Research, Inc. Caruso brings extensive experience in management and informatics from his former positions to his new role as Vice President of Informatics & Application Software for febit.

Dr. Stefan Matysiak, Vice President & General Manger of febit inc., stated, "We are really glad to welcome Anthony to our team. We are sure that he will enhance febit's bioinformatics expertise to a new and exciting level."

Since the beginning of 2007, the team of febit inc., directed by its Vice President & General Manager Dr. Stefan Matysiak, President Cord F. Staehler, CFO Jochen Kohlhaas and Vice President Business Development Peer Staehler, has been supported by Peter LaCrosse, Director of Operations and Sales Manager, Scott Magin. Mr. Caruso joins this growing team as the new Vice President of Informatics and Application Software.

Commenting on the team growth Dr. Matysiak said, "With Peter LaCrosse, febit gained a specialist in the area of international logistics, project management and project implementation, as well as extensive experience in customer service. Scott Magin possesses many years of field experience in the areas of Consulting, Sales and Services for the pharmaceutical and biotechnological industry. Anthony Caruso's responsibilities include the guidance of febit's application development and providing support for febit's US customer base. Thus, we have an ideal, complementary mix of qualifications within the team which will result in excellent performance of the company."

febit inc., an affiliated company of febit biotech gmbh from Heidelberg (Germany), commenced its operations in August, 2006 in Medford, Massachusetts (USA). During the last several months, febit inc. has built a powerful and competent team for Sales and Service by establishing an application lab for potential customers to test the Geniom Platform's ability to produce their specific requirements.

About Anthony Caruso
Anthony Caruso joined febit, Inc. in April 2007, as Vice President of Informatics & Application Software, where his responsibilities include the guidance of febit's application development and providing support for febit's US customer base. Prior to joining febit, Caruso held various positions during his 15 year professional career, including President and Founder of Source Code Genetics, Inc., an informatics consulting company focusing on decision support, data mining and data management; President and Managing Director of Lion bioscience Research, Inc., a five year, $100MM collaboration between Bayer Pharmaceuticals and Lion bioscience; Director II of Informatics and Automation at ALTANA Pharma; and Group Leader of Computational Biology at Genome Therapeutics. Mr. Caruso transitioned from the wet laboratory to informatics while at Genetics Institute, where his career started as a molecular biologist in the department of Hematopoiesis.

Hummingbird Diagnostics GmbH

Developing innovative and creative technologies for genomic research is the corporate mission of the febit group, a German-American biotech company. Geniom is a technological and service platform successfully used in basic and applied research of renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes providing superior time and cost efficiency combined with an unsurpassed spectrum of applications (Geno-, SNP- and Pathogentyping, Enzyme-on-Chip, miRNA-Profiling and many more). With the unique Geniom Technology febit now enters the high-potential market of synthetic biology with a novel method for production of synthetic genes. Using both, highly integrated automation and extensive customizability, febit meets essential needs of current biomedical research.